Following the release of encouraging clinical trial data, shares of NanoViricides, Inc. (NYSE: NNVC) are demonstrating a bullish trend on US stock charts. As of the latest current-market check, NNVC stock increased by 7.92% to $3.27.
- Breakthrough Findings On NV-387
- Efficacy Across Multiple Models
- Potential Revolutionary Antiviral Agent
Breakthrough Findings On NV-387
NanoViricides (NNVC) reported that its leading clinical-stage broad-spectrum antiviral drug candidate, NV-387, exhibits an ideal flat blood concentration profile for an extended duration upon oral administration in two different animal models. This rare but highly desirable extended flat time profile of NV-387 in the bloodstream enables a sustained antiviral effect over a prolonged period, allowing for infrequent dosing regimens.
Specifically, the blood concentration of NV-387 peaked within the first hour and remained nearly constant for eight hours or longer. Subsequently, the concentration declined to baseline at around twelve hours following the oral administration of the initial dose. This was consistently observed in studies involving rats and dogs.
Efficacy Across Multiple Models
Additionally, NanoViricides recently reported that when NV-387 was administered as a slow bolus intravenous infusion, it resulted in a relatively flat blood concentration plateau with a very slow decline over a 24-hour period in a cynomolgus monkey model. The company had previously demonstrated that orally administered NV-387 produced strong antiviral effects against several respiratory viruses.
In lethal infections with hCoV-NL63, RSV, and Influenza A/H3N2, orally administered NV-387 outperformed approved therapeutics where available. Notably, in a rat model of deadly lung infection with RSV A2, NV-387 allowed for the full recovery from RSV infection.
Potential Revolutionary Antiviral Agent
First-in-class, broad-spectrum antiviral medication NV-387, may revolutionize treatment for viruses including RSV, COVID-19, influenza, and maybe others. NNVC's claim is also supported by non-clinical pharmacokinetic studies of the medication when administered orally that NV-387's systemic circulation and direct antiviral actions are responsible for the strong antiviral effects shown in animal efficacy trials.
NanoViricides also highlighted that NV-387 may be among the first or one of the few nanomedicines effective upon oral administration, a notable advancement given that nanomedicines are typically restricted to injectable or topical delivery methods.
根據良好的臨床試驗數據,納米病毒滅活劑公司(NanoViricides,股票代碼:紐交所NNVC)在美國股票走勢上表現出看好的趨勢。迄今爲止的最新市場檢查顯示,NNVC股票價格上漲7.92%,至3.27美元。
- 關於NV-387的突破性發現
- 在多種模型中表現良好的有效性
- 具有潛在革命性的抗病毒藥物
關於NV-387的突破性發現
納米病毒滅活劑公司(NNVC)報告稱,其領先的臨床階段的廣譜抗病毒藥物候選者NV-387在兩種不同的動物模型中口服給藥後,體內呈現出理想的平穩血液濃度,可維持較長時間。NV-387在血液中持續平穩的時間延長,可使抗病毒效果持續很長時間,從而允許採用不頻繁的服藥方案。
具體而言,NV-387的血液濃度在首個小時內達到峯值,然後保持幾乎不變,持續八個小時或更長時間。隨後,在口服初始劑量後約十二小時時間內,濃度降至基線。在涉及大鼠和狗的研究中,這一結果始終如一。
在多種模型中表現良好的有效性
另外,納米病毒滅活劑公司最近報告稱,使用慢推注靜脈輸液途徑給予NV-387時,在短豬尾猴模型中,結果呈現出相對平穩的血液濃度平台,在24小時內緩慢下降。該公司此前已證明,口服NV-387對多種呼吸道病毒產生了強烈的抗病毒效果。
在hCoV-NL63,RSV和流感A/H3N2的致命感染中,口服NV-387表現出優於已批准的治療藥物的效果。值得注意的是,在與RSV A2致命肺部感染有關的大鼠模型中,NV-387使得從RSV感染中完全康復成爲可能。
具有潛在革命性的抗病毒藥物
領先的廣譜抗病毒藥物NV-387或許將革新治療RSV、COVID-19、流感等病毒的方法。NNVC公司的聲明也得到了藥物口服非臨床藥代動力學研究的支持。藥物在口服給藥時,NV-387的系統循環和直接抗病毒作用都是導致動物療效試驗呈現出強烈的抗病毒效果的原因。
此外,納米病毒滅活劑公司還強調,NV-387也許是口服給藥靶向性納米藥物中最先進或最少之一,這是一個被廣泛認可的進展,鑑於納米藥物通常只能採用注射或局部給藥方法。